Stipple Bio Announces Multi-Target Multi-Modality Oncology Research Collaboration with Lilly
Article excerpt
– Strategic research collaboration leverages Stipple Bio's innovative Pointillist Platform to identify tumor-specific cell surface epitope binders and Lilly’s proprietary oncology technologies – CAMBRIDGE, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Stipple Bio, Inc., a private biotechnology company harnessing epitope-level precision to create targeted cancer therapies, today announced that it has entered into a multi-target multi-modality strategic research collaboration and license agreement with Eli Lilly and Company (“Lilly”). Stipple Bio will leverage its innovative Pointillist Platform and extensive research experience to discover novel tumor-specific cell surface epitope binders, which Lilly will combine with its proprietary oncology technologies to advance high therapeutic index compounds across multiple modalities. Stipple Bio's Pointillist Platform identifies novel tumor-specific cell surface epitope binders to enable the development of high therapeutic index oncology therapies that selectively target tumor cells, with the potential to increase efficacy and reduce on-target, off-tumor toxicity. “Stipple Bio was founded with the belief that epitope-level precision could distinguish tumor cells from healthy tissue, unlocking a new generation of effective and safer cancer therapies directed at targets whose expression on healthy cells has historically limited their...
Keep reading with a free account
The rest of this article, and every signal for Eli Lilly, is in your free account.
Extracted from this sentence
Under the terms of the agreement, Stipple Bio will receive an upfront payment and an equity investment in Stipple Bio.